Postmenopausal Osteoporosis Market Research Report Information By Drug Class (Bisphosphonates, Selective Estrogen Receptor Modulators (SERMs), Anabolic Class, RANK Ligand Inhibitors, Calcium Metabolism Modifiers, and Others), By Route of Administration (Oral, Intravenous Route, and Subcutaneous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

Global Postmenopausal Osteoporosis Market Overview

The Postmenopausal Osteoporosis Market Size was valued at USD 9.7 billion in 2023. The Postmenopausal Osteoporosis Market industry is projected to grow from USD 10.2 billion in 2024 to USD 15.3 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.90% during the forecast period (2024 - 2032). Rising osteoporosis incidence among elderly females and increasing R&D and new drug approvals are the primary market drivers propelling the market's expansion.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Postmenopausal Osteoporosis Market Trends

Increasing demand for bisphosphonates is driving the market growth

The capacity of the bisphosphonates family of drugs to stop bone density loss and hence reduce fracture risk by 50% is predicted to account for the biggest proportion of the market. Moreover, most patients are able to take bisphosphonates over the long term. For instance, as per an article published in April 2021, named 'Bisphosphonate Prescriptions for Osteoporosis: Concerns In regards to Dangers and Side Effects,' by restraining osteoclast action, bisphosphonates diminish bone resorption, and various examinations have shown the way that this group of medications can increment bone thickness and lower break risk in those with low bone thickness. Because most patients with osteoporosis receive frequent prescriptions for them, it is anticipated that they will hold a sizable portion of the market under investigation.

Several bisphosphonates are often used to avoid and treat postmenopausal osteoporosis, including alendronate, risedronate, ibandronate, and zoledronic acid. A new regimen, including the intravenous approach, is being studied; positive trial results might further drive the bisphosphonate business throughout the anticipated time frame. The average five-year prescription for bisphosphonates lasts, and the drug's bone-protective effects last long after the course of therapy is stopped. Therefore, it is anticipated that the bisphosphate category would have a sizable market share in the postmenopausal osteoporosis market due to the considerations above.

Additionally, targeting certain processes involved in bone metabolism, such as sclerostin inhibition or the RANK ligand pathway, is the goal of biological treatments. Biologics can improve bone production and reduce bone resorption by carefully adjusting these pathways, providing a more focused and efficient method of treating osteoporosis, which is driving the market CAGR. In patients who are at high risk of fractures or who do not respond well to standard pharmacological medications, biologic therapies have proven to be more effective than traditional ones. This increased effectiveness may result in better results, such as decreased risk of fracture and increased density of bone mineral.

Furthermore, as per information distributed by the Worldwide Menopause Society (IMS), in 2021, more than 200 million ladies are assessed to experience the ill effects of osteoporosis, and 1 of every three ladies matured more than 50 is supposed to encounter osteoporosis fracture. Due to the previously mentioned factors, the concentrated market is supposed to develop over the estimated period. Thus driving the Postmenopausal Osteoporosis market revenue.

Postmenopausal Osteoporosis Market Segment Insights

Postmenopausal Osteoporosis Drug Class Insights

Based on Drug Class, the Postmenopausal Osteoporosis market segmentation includes bisphosphonates, selective estrogen receptor modulators (SERMs), anabolic class, RANK ligand inhibitors, calcium metabolism modifiers, and others. In 2023, the bisphosphonates segment dominated the market. Postmenopausal osteoporosis is treated with meds of the bisphosphonate family. By preventing bone resorption, it raises bone density in this way. Trends presently suggest a shift toward more contemporary biopharmaceuticals and accurate designated prescriptions, despite the fact that bisphosphonates have generally been a significant piece of osteoporosis treatment. However, market patterns suggest that patients are progressively more intrigued by inventive meds that might make fewer side impacts and better understand results. However, bisphosphonates are still frequently endorsed because of their shown adequacy. This improvement is an impression of the continuous mission for further developed and concentrated postmenopausal osteoporosis treatment.

The selective estrogen receptor modulators (SERMs) category is anticipated to be the fastest growing. Clinical experimentation has shown the viability of SERMs, for example, raloxifene, in decreasing the risk of vertebral fractures in postmenopausal ladies with osteoporosis. This decrease in break risk is a key component driving interest in SERMs as a treatment choice. Compared to standard hormone replacement therapy (HRT), SERMs provide a substitute for controlling postmenopausal side effects and reducing fractures caused by osteoporosis. They give a portion of the advantages of estrogen treatment, like bone protection, without the related dangers, like an expanded hazard of breast disease.

Postmenopausal Osteoporosis Route of Administration Insights

Based on the Route of Administration, the Postmenopausal Osteoporosis market segmentation includes oral, intravenous route, and subcutaneous. In 2023, the oral category generated the most income. Because it is more convenient and straightforward to administer, patients frequently choose the oral route. Because oral drugs don't require injections or infusions, patients are better able to comply with their treatment plans and stay compliant. Because oral administration is painless and often well tolerated by patients, it reduces the risk of infusion-related adverse events or infusion-site reactions that are typically associated with other administration methods.

Throughout the forecast period, the market for postmenopausal osteoporosis intravenous routes is expected to develop at the quickest rate. Certain drugs that treat osteoporosis, such as bisphosphonates (like zoledronic acid), are infused intravenously. One yearly or biennial dosage is a benefit of infusion therapy; this lowers the frequency of drug delivery and may increase patient convenience and adherence.

Postmenopausal Osteoporosis Distribution Channel Insights

Based on the Distribution Channel, the Postmenopausal Osteoporosis market segmentation includes hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies category leads the market. Patients can seek guidance and support services from retail drug stores, like assistance with adherence, portion guidelines, and medication directing. With regards to illuminating patients about their osteoporosis medicates, their side effects, and the benefit of adhering to treatment plans, drug specialists are essential. Patients generally visit retail drug stores to finish their solutions for osteoporosis drugs that clinical experts have suggested.

The Postmenopausal Osteoporosis market’s online pharmacies segment is anticipated to grow fastest during the projection period. For those with mobility impairments, who reside in rural locations, or who prefer to obtain drugs conveniently from the comfort of their homes, online pharmacies offer easy access to osteoporosis treatments.

Figure 1:  Postmenopausal Osteoporosis Market, by Distribution Channel, 2023 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Postmenopausal Osteoporosis Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Postmenopausal Osteoporosis market will dominate this market because of its developed medical care framework, presence of significant industry players, high diagnosis and therapy rate, more patient consistency, and huge patient base. The US contributes the most extreme offer in North America. About 18.8% of women who were 50 years of age or older had osteoporosis, according to data released by the Centers for Disease Control and Prevention (CDC) in 2021. Sedentary lifestyles and bad eating and drinking habits are expected to contribute to the pervasiveness even further. Approximately 71 million Americans are expected to have reduced bone density and osteoporosis by 2030, according to the Public Osteoporosis Establishment.

Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2:  POSTMENOPAUSAL OSTEOPOROSIS MARKET SHARE BY REGION 2023 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe's Postmenopausal Osteoporosis market accounts for the second-largest market share. Europe's population is among the oldest in the world, and a significant number of postmenopausal women live in regions where osteoporosis is more common. The demographic shift towards an aging population creates an important market for osteoporosis prevention, diagnosis, and treatment. Further, the German Postmenopausal Osteoporosis market held the largest market share, and the UK Postmenopausal Osteoporosis market was the fastest-growing market in the European region.

The Asia-Pacific Postmenopausal Osteoporosis Market is expected to grow at the fastest CAGR from 2024 to 2032. Numerous nations in the Asia Pacific are putting resources into extending their healthcare framework, further developing admission to healthcare administrations, and reinforcing primary care systems. This development of healthcare facilities and services upgrades opportunities for osteoporosis screening, analysis, and therapy. Moreover, China’s Postmenopausal Osteoporosis market held the largest market share, and the Indian Postmenopausal Osteoporosis market was the fastest-growing market in the Asia-Pacific region.

Postmenopausal Osteoporosis Key Market Players & Competitive Insights

The industry's leading players will keep investing heavily in R&D to expand their product lines, which will propel the growth of the postmenopausal osteoporosis market. Contractual contracts, mergers and acquisitions, increased investments, collaboration with other companies, and the production of new products are examples of significant market developments. To increase their worldwide reach, market players also take part in a variety of strategic initiatives. In order to survive and expand in a more competitive and dynamic market, the Postmenopausal Osteoporosis industry must offer reasonably priced products and services.

One of the main strategies manufacturers use in the worldwide Postmenopausal Osteoporosis market is local manufacturing, which expands the market sector and helps customers by lowering operating costs. Some of the biggest medical benefits in recent years have come from the Postmenopausal Osteoporosis sector. Major players in the Postmenopausal Osteoporosis market, including Pfizer Inc., Amgen, F. Hoffmann-La Roche Ltd, Novartis AG, Chugai Pharma China Co., Ltd., Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, Hikma Pharmaceuticals PLC, GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd, Paras Biopharmaceuticals Finland Oy, Ligand Pharmaceuticals Incorporated, and Eli Lilly and Company, and others, are attempting to increase market demand by investing in research and development operations.

Pfizer Inc (Pfizer) discovers, creates, makes, and markets biopharmaceuticals. The organization offers items to treat different circumstances, such as cardiovascular, metabolic, and pain, ladies' well-being, malignant growth, inflammation, resistant problems, and rare illnesses. It additionally gives clean injectable drugs, biosimilars, active pharmaceutical ingredients (APIs), and agreement-producing services. Pfizer sells its items through wholesalers, retailers, medical clinics, individual supplier workplaces, facilities, government organizations, and drug stores. Pfizer Inc. brought back to the U.S. market DUAVEE (conjugated estrogens/bazedoxifene), a menopausal hormone treatment with estrogen, in June 2023 with improved packaging. This return follows a voluntary recall due to a packaging problem that had nothing to do with any worries about the efficacy or safety of the product. It is anticipated that this relaunch plan will address the packaging concerns and increase sales income.

Amgen Inc., a biotechnology business, finds, makes, produces, and distributes state-of-the-art human meds to treat patients with hazardous sicknesses. It makes state-of-the-art prescriptions to address afflictions connected with the heart, hematological and oncology, irritation, bone well-being, neurological sicknesses, and nephrology. To make merchandise that uses state-of-the-art human hereditary qualities, the association inspects the difficulties presented by sickness and appreciates the standards of human science. Amgen mainly supplies pharmaceutical wholesale wholesalers in the United States with its goods. Additionally, it markets some items directly to customers through collaborations with other businesses and direct-to-consumer channels. Amgen's latest findings from real-world research in 2023 show that Prolia was very successful in lowering the risk of fracture in individuals with postmenopausal osteoporosis.

Key companies in the Postmenopausal Osteoporosis market include

• Pfizer Inc.


• Amgen


• Hoffmann-La Roche Ltd


• Novartis AG


• Chugai Pharma China Co., Ltd.


• Teva Pharmaceutical Industries Ltd.


• Fresenius Kabi AG


• Hikma Pharmaceuticals PLC


• GlaxoSmithKline plc


• Sun Pharmaceutical Industries Ltd


• Paras Biopharmaceuticals Finland Oy


• Ligand Pharmaceuticals Incorporated


• Eli Lilly and Company

Postmenopausal Osteoporosis Industry Developments

July 2022: Edirol (eldecalcitol) was introduced in China by Chugai Pharma China Co., Ltd., a division of Chugai Pharmaceutical Co., Ltd., following clearance by the China National Medical Products Administration (NMPA) for the management of postmenopausal osteoporosis. Chugai developed edirol, an effective vitamin D3 derivative.

January 2021: Released by the Asia Pacific Consortium on Osteoporosis (APCO), the guidelines provide clinical practice for osteoporosis screening, diagnosis, and care throughout the Asia-Pacific region. The guidelines prioritize the needs of several high-risk populations. In addition to strengthening the Asia-Pacific sector, the project is expected to increase awareness in the region even further.

Postmenopausal Osteoporosis Market Segmentation

Postmenopausal Osteoporosis Drug Class Outlook

• Bisphosphonates


• Selective Estrogen Receptor Modulators (SERMs)


• Anabolic Class


• RANK Ligand Inhibitors


• Calcium Metabolism Modifiers


• Others

Postmenopausal Osteoporosis Route of Administration Outlook

• Oral


• Intravenous Route


• Subcutaneous

Postmenopausal Osteoporosis Distribution Channel Outlook

• Hospital Pharmacies


• Retail Pharmacies


• Online Pharmacies

Postmenopausal Osteoporosis Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America